Potential impact of NUCB2 genetic variants with the clinicopathological characteristics of prostate cancer Authors: Yung-Shu Lee, Tien-Huang Lin, Chia-Yen Lin, Shun-Fa Yang, Chiao-Wen Lin, Chih-Hsin Tang Published: 2026 ABSTRACT The most prevalent illness in men is prostate cancer, which risk increases with age and obesity. The precursor NUCB2 gene produces the adipokine nesfatin-1, which was first found in hypothalamic neurons. It is currently unclear how NUCB2 polymorphisms, cancer-promoting lifestyle factors, and prostate cancer are related. We investigated the relationship between clinicopathological features and 4 NUCB2 gene polymorphisms in prostate cancer when compared to healthy individuals. Compared with the wild-type T/T genotype, carriage of at least one G allele (T/G or G/G genotypes) at the NUCB2 SNP rs10766383 was linked with a declined risk of clinical T3+T4 stage, pathologic T3+T4 stage, and perineural invasion. In addition, the TG/GG genotypes at rs10766383 were also associated to a lower risk of clinical T3+T4 stage and perineural invasion in patients with biochemical recurrence. Importantly, GTEx data indicated that the wild-type TT homozygous genotype was linked with markedly higher NUCB2 levels compared to the GG allele of variant rs10766383 variant in mucosa and whole blood tissues. Thus, the NUCB2 SNP rs10766383 may play a protective function against prostate cancer progression. Introduction Prostate cancer is the most typical disease in males, and its risk elevates with age and obesity 1-3. By 2050, there will likely be 300,000 new prostate cancer patients in the United States. More than half of prostate cancer patients ultimately develop bone metastases, notably in advanced stages, even though many first show up with organ-confined disease 2, 4-6. In addition, bone, lymph nodes, and distant organs are common sites of metastasis, which results in a poor prognosis and decreased survival. Many individuals with metastatic cancer develop treatment-resistant disease, despite the five-year associate survival rate for combined diagnosed cases of prostate cancer is 98%. Prostate cancer metastases are a critical cause of mortality and can markedly reduce patients' quality of life 7-9. The development of early diagnostic and prevention strategies would be aided by a thorough understanding of the mechanisms behind distant metastasis and malignant progression in prostate cancer 10, 11. There is mounting evidence that obesity and cancer are related 12, 13. The malignancies where this relationship is most apparent are pancreatic, colorectal and prostate cancers 12, 14, 15. Additionally, obesity can alter the cancer's microenvironment, accelerating its growth 16. Adipokines, bioactive compounds secreted by adipose tissue, regulate numerous pathological processes 17. Among other characteristics of cancer, adipokines have an impact on apoptosis, angiogenesis, differentiation, invasion, proliferation and metastasis 18-20. Originating from its precursor NUCB2, nesfatin-1 is an 82-amino acid polypeptide that was initially identified in hypothalamus neurons 21. Other peripheral tissues that express nesfatin-1 include adipose tissue, the ovaries, the duodenum, and the pancreas 22. Nesfatin-1 has been proposed as an anorexigenic peptide having antihyperglycemic, antioxidant and anti-inflammatory characteristics 23, 24. Increased expression of NUCB2 has been seen in colon, endometrial, prostate, thyroid and breast cancers, according to recent research 25. These results show that nesfatin-1 levels are strongly associated with a poor prognosis, as shown by the development of metastases and a lower life expectancy free from recurrence. A single nucleotide variant that appears at a particular site in the genome is known as a single nucleotide polymorphism (SNP) 26. SNP distribution frequency analysis between patient cohorts is commonly used to predict the risk and prognosis of diseases like cancer 27, 28. There is no information on the connections between prostate cancer, NUCB2 gene polymorphisms, and carcinogenic behavioral factors. Thus, this investigation examined the functions of NUCB2 gene polymorphisms and carcinogenic lifestyle variables on the risk of progressing prostate cancer in a Taiwanese population. Materials and Methods Study participants This study examined blood samples from 697 prostate cancer patients who underwent robotic-assisted laparoscopic radical prostatectomy at Taichung Veterans General Hospital (TVGH; Taichung, Taiwan) between 2012 and 2018. All subjects gave written informed consent prior to venous blood collection, and the investigation procedure was approved by the TVGH Institutional Review Board. Medical data collected at the time of diagnosis included prostate-specific antigen (PSA) levels, pathologic Gleason grades, clinical and pathologic T (tumor) and N (node) staging, cancer invasion sites (seminal vesicle, perineural, and lymphovascular regions) 29, D'Amico classification, and the biochemical recurrence (BCR) status 30. Selection and genotyping of SNPs Based on other publications 31, 32, the NUCB2 SNPs rs1330, rs214101, rs757081, and rs10766383 were chosen. Every SNP exhibited a minor allele frequency higher than 5%. 3 mL peripheral blood samples were used to extract genomic DNA using QIAamp DNA Blood Kits (Qiagen, CA, USA). Allelic discrimination was applied to the SNPs using previously established evaluation methods 33. The procedures we previously described 34, 35 were followed for RT-qPCR tests and RNA isolation. Analysis of clinical dataset The GTEx portal (gtexportal.org/home/) is a comprehensive public resource for examining tissue-specific gene level and modulation. It provides open-access gene expression data, histology pictures, and quantitative trait loci (QTLs) 36. Statistical analysis The Mann-Whitney U test and Fisher's exact test were used to evaluate the differences between the prostate cancer and control groups; p-values less than 0.05 were deemed statistically significant. Odds ratios (ORs) and their 95% confidence intervals (CIs) for the relationships between genotype frequencies and prostate cancer risk were computed using logistic regression. The Statistical Analytic System (SAS) software, version 9.1, was used to evaluate the gathered data. Results The demographic and clinical features of 697 male Taiwanese patients with prostate cancer and 806 cancer-free healthy controls are distributed in Table 1. The prostate cancer group had a significantly larger proportion of patients over 65 (57.8%, n = 403) compared to the control group (11.7%, n = 94) (p < 0.001). Patients were more likely to exhibit pathologic Gleason scores of 1+2 (60.0%, n = 418), clinical T1 or T2 stages (86.2%, n = 601), pathologic T2 stage (52.9%, n = 369), and pathologic N0 stage (91.4%, n = 637). Patients presented with no seminal vesicle invasion (78.8%, n = 549) and no lymphovascular invasion (84.1%, n = 586). Furthermore, patients were classified as high-risk according to the D'Amico risk classification (66.2%, n = 352) and as having a low risk of BCR (68.6%, n = 478). Table 2 exhibits the genotyping data for the NUCB2 SNPs in health controls and patients with prostate cancer. The predominant genotypes were homozygous C/C for rs1330 and rs757081, homozygous G/G for rs214101, and homozygous T/T for rs10766383. None of the genotypes for the four NUCB2 SNPs across the comparison groups showed a strong connection with prostate cancer after controlling for age (Table 2). The distributions of clinical features and NUCB2 genotypes within patients with prostate cancer were then compared. SNPs rs1330, rs214101 and rs757081 did not significantly affect clinicopathologic characteristics in patients with prostate cancer (Table 3&4). However, patients carrying at least one polymorphic G allele at rs10766383 (T/G + G/G genotypes) showed a lower risk of progression to clinical T3 or T4 stages (OR = 0.623; 95% CI: 0.394-0.983; p < 0.05), pathologic T3 or T4 stage (OR = 0.683; 95% CI: 0.488-0.956; p < 0.05), and perineural invasion (OR = 0.553; 95% CI: 0.365-0.836; p < 0.05) compared with the T/T genotype (Table 4). Importantly, the TG or GG genotypes at rs10766383 were associated with a reduced risk of clinical T3 + T4 stages (OR = 0.446; 95% CI: 0.234-0.849; p < 0.05) and perineural invasion (OR = 0.129; 95% CI: 0.017~0.990; p < 0.05) (Table 5) in patients with BCR. The GTEx data showed that in mucosa and whole blood tissues, patients with the wild-type TT homozygous genotype had significantly higher levels of NUCB2 than those with the GG allele of variant rs10766383 (p < 0.05; Figure 1). Discussion The usefulness of biomarkers based on genetic abnormalities associated with malignancies in assessing risk, supporting prompt diagnosis, and forecasting treatment outcomes has been documented by different cancer studies 37, 38. Genetic polymorphisms, or individual differences in genomic sequences, are present in about 1% of the population. SNPs are the most common type of changes seen in repetitive sequences 39. The relevance of SNPs and other genetic alterations in defining and predicting pharmacotherapeutic actions in prostate cancer has lately been pointed out by a growing body of investigation 40. The significance of SNPs in tumor biology has also been highlighted by the systematic identification of functional variations associated with cancer risk, which has shown how SNPs in functional regions impact gene level and tumor susceptibility 39. NUCB2 gene polymorphisms have been linked to oral cancer 33. However, the relation between NUCB2 polymorphisms and prostate cancer still unknown. Therefore, we examined polymorphisms in the NUCB2 gene and observed their differential distribution within prostate cancer patients. Our data indicated that the NUCB2 SNP rs10766383 is linked with a declined risk of clinical T3+T4 stage, pathologic T3+T4 stage, and perineural invasion. The development of prostate cancer is markedly associated by adipose tissue 41. Tumor cell proliferation, invasion, and metastasis are thought to be impacted by prostate cancer's direct or indirect interactions with adipocytes. Interestingly, the most common metastatic location in prostate cancer is bone 42, 43. Bone marrow adipocytes have been implicated in the formation and exacerbation of these bone metastases in a number of cases 44. For the past 20 years, numerous researchers have been examining the function of adipose tissue in the development of carcinogenesis and inflammation 45. Nesfatin-1 is essential for cell proliferation and the stimulation of cancer cell apoptosis, according to recent findings 25. Thyroid, breast, and colon cancer tissues had higher levels of nesfatin-1 than nearby non-cancerous tissues 46-48. Furthermore, in renal cell carcinoma, elevated nesfatin-1 expression was closely associated with advanced tumor stage and metastasis 49. In this work, we compared the genotypic and allelic distributions of NUCB2 gene polymorphisms between patients with prostate cancer and health controls. The four NUCB2 SNPs and total susceptibility to prostate cancer did not differ significantly. However, when we stratified prostate cancer patients according to clinical parameters, carriers of at least one G allele (T/G + G/G genotypes) at the NUCB2 SNP rs10766383 were protected against developing clinical T3+T4 stage, pathologic T3+T4 stage, and perineural invasion. Importantly, GTEx data indicated that the wild-type TT homozygous genotype was linked with markedly higher NUCB2 expression levels compared to the GG allele of variant rs10766383 variant in mucosa and whole blood tissues. Thus, NUCB2 SNP rs10766383 may act as a negative factor of prostate cancer progression. After radical prostatectomy or radiation therapy, BCR is a common clinical occurrence in PCA patients. An increasing PSA level, which suggests potential tumor recurrence or metastasis prior to the onset of clinical symptoms, is a common characteristic of BCR. In order to assess therapy results, forecast disease development, and direct future therapeutic approaches in PCA care, BCR monitoring is crucial. However, a rise in PSA levels following definitive treatment, such as surgery or radiation therapy, without any clinical or radiographic signs of illness is referred to as a prostate cancer BCR. It frequently shows recurrent or residual tumor activity and may precede the development of metastases, directing choices about salvage therapy or additional monitoring 9, 50, 51. In the current study, we also demonstrated that the TG or GG genotypes at rs10766383 were associated with a reduced risk of clinical T3 + T4 stages and perineural invasion compared with the TT genotype in patients with BCR. Therefore, the NUCB2 SNP rs10766383 also plays a protective role in prostate cancer with BCR. Finally, we should acknowledge the limitations of the current study. Although we found that the NUCB2 SNP may play a protective role against prostate cancer progression, our study has several limitations. First, we lacked sufficient prostate cancer and normal control tissue samples for immunohistochemical staining. Therefore, further studies are needed to examine nesfatin-1 expression in prostate cancer patients and normal individuals to validate and support our SNP findings. In summary, our investigation is the first to identify an association between NUCB2 gene variants and prostate cancer. Compared with the wild-type T/T genotype, carriage of at least one G allele (T/G or G/G genotypes) at the NUCB2 SNP rs10766383 was linked with a declined risk of clinical T3+T4 stage, pathologic T3+T4 stage, and perineural invasion. In addition, the TG/GG genotypes at rs10766383 were also linked to a lower risk of clinical T3+T4 stage and perineural invasion in patients with BCR. Our results suggest that NUCB2 SNPs may play a critical role in prostate cancer progression and perineural invasion.